ADCs targeting BCMA, CD38, CD46, CD56, CD74, CD138 are not discussed here since this special issue contains another article devoted to ADCs in multiple myeloma [184], and these targets are mainly explored in this disease setting. The gene discussed is NCAM1; the disease is plasma cell myeloma.